Exchange: NYSE·Updated 07:38 PM EDT

NVS News

News
all
press releases
Why Is Merck (MRK) Up 18.2% Since Last Earnings Report?
Merck (MRK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
More News
Novartis' Remibrutinib Delivers Positive Results in Late-Stage MS Studies
Novartis' remibrutinib delivers positive phase III RMS results, reducing relapse rates versus Aubagio and supporting plans for global regulatory approvals.
Zacks
TGTX Stock Pares Opening Losses After Analyst Dismisses Competition From Novartis
TGTX shares opened lower on Tuesday after Novartis said its drug remibrutinib improved multiple sclerosis in late-stage trials.
Stocktwits
Swiss Market Closes Higher Boosted By Novartis MS Drug Results
(RTTNews) - The Switzerland market closed on a positive note on Tuesday despite struggling for direction for much of the day's session. Geopolitical tensions, high oil prices and concerns about the outlook for interest rates and global economic growth rendered the mood cautious...
Nasdaq News: Markets
The Multiple Sclerosis Drug Race Just Got Hotter After Novartis' Phase 3 Win
Novartis stock spikes 5% on positive Phase 3 REMODEL trial results for relapsing MS drug remibrutinib with no liver safety signals.read more...
Benzinga
Novartis shares up following positive trial data of new multiple sclerosis drug
Novartis shares up following positive trial data of new multiple sclerosis drug...
CNBC Television-YouTube
Oncology Stocks to Add to Your Portfolio as Cancer Care Evolves
Oncology innovation is driving new treatment options, with Iovance, Merit Medical and Kura advancing cancer-focused therapies and technologies.
Zacks
FDA Nods Lilly-Roche's Alzheimer's Blood Test: Healthcare ETFs to Track Now
FDA clearance of Lilly and Roche's Alzheimer's blood test highlights a growing diagnostics market and four healthcare ETFs to watch.
Zacks
Common Blood Pressure Drug Recalled Nationwide, FDA Says
Common Blood Pressure Drug Recalled Nationwide, FDA Says Authored by Jack Phillips via The Epoch Times, Novartis Pharmaceuticals Corporation recalled some heart failure and high blood pressure medication due to potency issues, according to the Food and Drug Administration's...
Zero Hedge
FDA Approval Nearly Doubles Eligible Patient Pool For Novartis' Pluvicto
FDA approves Novartis' Pluvicto for earlier-stage metastatic prostate cancer, nearly doubling eligible patients.read more...
Benzinga

Advertisement|Remove ads.